OSTX News

OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma Ready to Announce with Confidence?

OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma Ready to Announce with Confidence?

OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma Ready to Announce with Confidence?

OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World Ready to Announce with Confidence?

OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences Ready to Announce with Confidence?

OS Therapies Reports First Quarter 2026 Financials and Provides Business Update Ready to Announce with Confidence?

OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 Ready to Announce with Confidence?

OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor Ready to Announce with Confidence?

Stonegate Capital Partners Updates Coverage on MarketWise (MKTW) 1Q26 Ready to Announce with Confidence?

Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) Ready to Announce with Confidence?